Initial Results from a Phase 1 Study of TQB2934, a BCMA x CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

被引：0

作者：

Liu, Peng ^{[1
,2
]}

Zhuang, Junling ^{[3
]}

Xia, Zhongjun ^{[4
]}

Li, Bingzong ^{[5
]}

Jiang, Songfu ^{[6
]}

Zhang, Yian ^{[1
]}

Wang, Wei ^{[7
]}

Chen, Xiaoqin ^{[8
]}

Zhang, Xiaohui ^{[9
]}

Zhou, Shujuan ^{[10
]}

机构：

[1] Fudan Univ, Zhongshan Hosp, Hematol, Shanghai, Peoples R China

[2] Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China

[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Hematol, Beijing, Peoples R China

[4] Sun Yat Sen Univ, Dept Hematol Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China

[5] Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou, Peoples R China

[6] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China

[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[8] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Dept Hematol Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China

[9] Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China

[10] Wenzhou Med Univ, Affiliated Hosp 1, Hematol, Wenzhou, Peoples R China

来源：

关键词：

D O I：

10.1182/blood-2024-209665

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1998 / 1999

页数：2